Business, energy, technology, markets and global industry news from Business News Today

Lenacapavir

PharmaDeviceNews Lenacapavir
Gilead Sciences and Merck’s investigational once-weekly HIV pill maintained virological suppression in the Phase 3 ISLEND-1 and ISLEND-2 trials. Representative image.
Pharma & Biotech

Can one HIV pill a week replace daily therapy? Gilead and Merck’s Phase 3 data raise the stakes

Gilead and Merck’s weekly HIV pill preserved suppression in two Phase 3 trials, strengthening the case for regulatory filings.

Read More
Representative image of an HIV prevention consultation, as Gilead Sciences’ once weekly oral Yeztugo filing puts long acting PrEP and future FDA review in focus.
Pharma & Biotech

Gilead’s once weekly Yeztugo bid could challenge the old daily pill versus injection divide

Read how Gilead’s once weekly oral Yeztugo filing could reshape HIV prevention, PrEP adherence and long acting therapy competition.

Read More
Representative image of biopharma laboratory research. Gilead Sciences and Merck’s latest Phase 3 updates highlight the promise of once-weekly HIV treatment with islatravir and lenacapavir, while raising fresh questions over Trodelvy’s lung cancer expansion strategy.
Pharma & Biotech

Gilead and Merck pipeline update reveals promise in HIV and pressure in oncology

Gilead and Merck gain HIV momentum but face fresh oncology questions. See why this split pipeline update matters.

Read More
Pharma & Biotech

Gilead expands its HIV playbook as lenacapavir moves from niche drug to platform strategy

Gilead’s CROI 2026 data highlight lenacapavir’s evolution into a platform for HIV treatment and prevention. Explore what this changes for clinicians and regulators.

Read More